This is how much the US is spending on Alzheimer's

A resident holds the hand of a nurse at the SenVital elderly home in Kleinmachnow outside Berlin May 28, 2013. Facing an acute shortage of skilled applicants among its own workforce, German institutions in the care sector increasingly turn to southern European countries to hire trained nursing staff who are willing to work abroad despite the language barrier in order to escape unemployment at home. The SenVital home for the elderly outside Berlin has accepted five qualified nurses from Spain as their staff, providing eight months of language training and additional care schooling needed to attain the German nursing concession.  Some 100 Spaniards applied for the ten vacancies SenVital had advertised across its various houses.  REUTERS/Thomas Peter (GERMANY  - Tags: HEALTH BUSINESS EMPLOYMENT) - RTX103ZD

A new report from the Alzheimer's Association examines how much the US is spending on treating the disease. Image: REUTERS/Thomas Peter

Lydia Ramsey
Editorial Intern, Business Insider Science

Alzheimer's disease is the only one of the top leading causes of death whose progression can't be slowed down or stopped.

The neurodegenerative disease affects about 5.5 million Americans, a number that's expected to balloon to 13.8 million by 2050.

And the amount spent caring for people with Alzheimer's is expected to reach $259 billion in 2017, according to a report released Tuesday by the Alzheimer's Association.

"Everybody with a brain at risk and needs to care about this," Beth Kallmyer, vice president of constituent services for the Alzheimer’s Association told Business Insider.

The search for a treatment to Alzheimer's hasn't been going well. There are only four approved drugs that treat symptoms of the disease, and several hopeful treatments have failed key studies over the last few months.

So while death rates for illnesses such as HIV and heart disease have dropped over the past 14 years, the Alzheimer's Association noted, Alzheimer's deaths are up 89% over that period.

Image: Alzheimer's Association

Still, more drugs are in late-stage trials that could have an impact on the disease, and researchers are pinning hopes on diagnosing the disease early, before symptoms even show up. If any of those treatments pan out, it could change the way we look at the disease and potentially make these statistics a lot less dire.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Stay up to date:

United States

Share:
The Big Picture
Explore and monitor how United States is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum